Renibus Therapeutics Announces Oral Presentation on RBT-1 Phase 2 Results at 2023 Society of Critical Care Medicine (SCCM) Meeting
Renibus Therapeutics Announces Oral Presentation on RBT-1 Phase 2 [...]
Renibus Therapeutics Announces Positive 30-Day Topline Data from RBT-1 Phase 2 Trial
Renibus Therapeutics Announces Positive 30-Day Topline Data from RBT-1 [...]
Renibus Therapeutics Strengthens Leadership Team with Asha Ramdas as SVP, Program Management, Technical Operations and Manufacturing
Renibus Therapeutics Strengthens Leadership Team with Asha Ramdas as [...]
Renibus Therapeutics Raises $33 million Bridge Financing to Advance its Portfolio of Cardiorenal Product Candidates
Renibus Therapeutics Raises $33 million Bridge Financing to Advance [...]
Renibus Therapeutics Presents Interim Phase 2 Data: RBT-1 Improves Post-Operative Outcomes in Cardiac Surgery Patients During Oral Session at AHA Scientific Sessions 2022
Renibus Therapeutics Presents Interim Phase 2 Data: RBT-1 Improves [...]